FALSE0001801170CLOVER HEALTH INVESTMENTS, CORP. /DE00018011702023-06-052023-06-05

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 5, 2023

CLOVER HEALTH INVESTMENTS, CORP.

(Exact name of Registrant as Specified in Its Charter)

Delaware
001-3925298-1515192
(State or Other Jurisdiction
(Commission File Number)
(IRS Employer
of Incorporation)
Identification No.)
3401 Mallory Lane, Suite 210
Franklin, Tennessee
37067
(Address of Principal Executive Offices)(Zip Code)

Registrant’s Telephone Number, Including Area Code: (201) 432-2133

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:

Trading
Title of each class
Symbol(s)
Name of each exchange on which registered
Class A Common Stock, par value $0.0001 per shareCLOVThe NASDAQ Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On June 5, 2023, Joseph Martin notified Clover Health Investments, Corp. (the “Company”) that he will be resigning as General Counsel and Corporate Secretary of the Company, effective as of June 16, 2023, in order to pursue a new role at a public company.

“Joe has been a fantastic partner in helping steer us during this formative time as a young public company. I’m always delighted that we produce such fantastic Clover alumni and I think Joe has a wonderful opportunity in front of him” said Andrew Toy, Chief Executive Officer of the Company.

“I’ve enjoyed and appreciate my time spent with Clover and continue to deeply believe in its mission to bring great healthcare to the underserved while making Medicare more sustainable to society. I’ll always be a Clover supporter and wish Andrew and the rest of the team all the best success.” said Joe Martin.


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


Clover Health Investments, Corp.
Date:June 8, 2023By:/s/ Scott J. Leffler
Name:Scott J. Leffler
Title:Chief Financial Officer


Social Capital Hedosophi... (NYSE:IPOC)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Social Capital Hedosophi... Charts.
Social Capital Hedosophi... (NYSE:IPOC)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Social Capital Hedosophi... Charts.